Innovent and Lilly Report Results of Tyvyt (sintilimab) in Seven Clinical Studies to be Presented at the ESMO ASIA Congress 2020
Shots:
- The 7 studies include one Proffered Paper Oral Presentation & 6 e-posters- covering indications including lung cancer- liver cancer- gastric cancer- & esophageal cancer
- The 1st study involves assessing of sintilimab + bevacizumab biosimilar vs sorafenib as 1L treatment for aHCC while the 2nd study includes assessing of sintilimab + anlotinib as 1L therapy in patients with aHCC. The 3rd study evaluates sintilimab + docetaxel in patients with previously treated advanced NSCLC while the 4th study evaluates autologous CIK cell immunotherapy + sintilimab + CT in patients with advanced NSCLC
- 5th study includes assessing of neoadjuvant sintilimab + triplet CT for resectable ESCC- 6th study assesses sintilimab + FLOT regimen for neoadjuvant treatment of GEJ adenocarcinoma while 7th study assesses perioperative sintilimab + concurrent CRT for LA gastric or GEJ adenocarcinoma
Ref: PRNewswire | Image: Fortune
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
